Richard Francis, Teva CEO
August 2, 2023 11:11 AM EDTUpdated 04:06 PM
Pharma
Manufacturing

Te­va sees rev­enue in­creas­es in Q2 as it con­tin­ues its ‘piv­ot to growth’ dri­ve

Tyler Patchen

News Reporter

Te­va is con­tin­u­ing its “piv­ot to growth” ini­tia­tive by mark­ing an in­crease in rev­enue for the sec­ond quar­ter.

The phar­ma

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times